Navigation Links
Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity
Date:3/10/2008

e (day 22 post inoculation). Administration of ANAVEX 7-1037 was stopped when tumors of the control group had grown to approximately 1,000 cubic millimeters (day 33 post inoculation).

Dacarbazine was used as a control drug and was administered for five consecutive days at a dose of 80 mg/kg. Each group consisted of at least seven animals, which is equal to 14 tumors or two tumors per mouse.

Under the experimental conditions tested, the control drug Dacarbazine did not show any measurable activity against this patient-derived xenograft. In contrast, ANAVEX 7-1037 exhibited significant activity at dosage levels of 100 mg/kg. A deltaT/deltaC score of 31% was demonstrated, where T is equal to the animals treated with ANAVEX 7-1037 and C is equal to the untreated control group, meaning that tumor growth volume was reduced by 69% more in the ANAVEX 7-1037 group than in the control group. The 31% score achieved with ANAVEX 7-1037 is far better (lower) than the 42% deltaT/deltaC score standard set by the U.S. National Cancer Institute (NCI) to characterize a compound as a potent anti-cancer drug. These noteworthy results were achieved after ANAVEX 7-1037 had been administered seven times at a statistically significant level (post inoculation day of cancer cells, or p.i.d.=33, tumor size, or p<=0.001) when compared to the tumors of the untreated control mice. The 70 mg/kg dose of ANAVEX 7-1037 showed an effect on the tumors that was quite close to the NCI criterion of the 42% limit, again with the best deltaT/deltaC values (p.i.d.=33, deltaT/deltaC=45%, p=0.003) after the seventh dose of ANAVEX 7-1037 was administered. The remaining doses that were administered (at 40 and 10 mg/kg) showed a dose-dependent effect on the tumors but with no significant importance. No significant weight loss was recorded during the period of the experiment.

ANAVEX continues to conduct experiments in xenografts with a focus on melanoma and other tumors that in-vitro methodolo
'/>"/>

SOURCE Anavex Life Sciences Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Anavex strengthens Board of Directors
2. Anavex advances drug candidate for treatment of Alzheimers disease
3. New Dual Cold Probe From Varian, Inc. Increases Sensitivity and Reduces Analysis Times for 13C NMR Experiments
4. Drug Reduces Airway Mucus in Preclinical Asthma Model
5. Heavier hydrogen on the atomic scale reduces friction
6. ANX-514 Reduces Hypersensitivity Reactions Without Impacting Pharmacokinetics or Antitumor Activity in Preclinical Tests
7. New Phase III Data Demonstrate Oxycodone / Naloxone Combination Tablet Reduces Opioid-Induced Bowel Dysfunction in Patients With Chronic Severe Pain
8. Landfill mining reduces environmental impact of growing waste
9. Landfill mining reduces environmental impact of growing waste
10. First-Ever Cancer and Careers Seminar Debuts in Orange County
11. Assembly technique for tiny wires may eventually help detect cancer and other diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014  CorMedix Inc. (NYSE MKT: ... commercializing therapeutic products for the prevention and treatment ... of notice on July 18, 2014 from the ... accepted the CorMedix plan to regain compliance with ... result, the NYSE-MKT is continuing the Company,s listing ...
(Date:7/24/2014)... 2014 Deep Research Report on ... professional and in-depth research report on Potassium Sulphate ... basic information, including its definition, classification, application, and ... covers the international market analysis, including China’s domestic ... macroeconomic environment & economic situation analysis, the influence ...
(Date:7/24/2014)... , July 24, 2014 WIRB-Copernicus Group ... regulatory and ethical review services for clinical research, ... Formerly a division of Richmond, VA ... leading biosafety and biosecurity consulting firm in ... addition, WCG,s biosafety division – WCG Biosafety™ – ...
(Date:7/24/2014)... Canada (PRWEB) July 24, 2014 The ... Optimizing Dose Escalation in First in Human Studies” will ... make better go/no-go decisions. , With increasing R&D costs ... pharmaceutical companies need to maximize the knowledge collected in ... decisions and improve success in late stage development. , ...
Breaking Biology Technology:CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 2Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 3Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 4WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 2WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 3Best Practices for Optimizing Dose Escalation in First in Human Studies, New Webinar August 6th Hosted by Xtalks 2
... 19 LI-COR Biosciences has released a,new ... gels the Odyssey Infrared,Imaging System. The E-PAGE ... provide a high-throughput SDS-PAGE,method for processing protein samples. ... Blotting System, up to 96 different proteins samples ...
... Michigan-based platform company has been built upon the foundation of a ... dynamically build themselves on a wide variety of computational platforms. The ... sagging Michigan economy through the creation of thousands of new jobs ... ...
... Md., Nov. 19 PharmAthene, Inc.,(NYSE Alternext US: ... and chemical threats, announced today that,it has signed ... its,biodefense products in Israel. , ... countermeasures to combat the risk of,terrorist attacks with ...
Cached Biology Technology:Technical Note: E-PAGE(TM) 48- and 96-Well Gels on the Odyssey(R) Infrared Imaging System 2Michigan Company Founded upon What Could Be History's Most Important Breakthrough in AI and Robotics 2Michigan Company Founded upon What Could Be History's Most Important Breakthrough in AI and Robotics 3Michigan Company Founded upon What Could Be History's Most Important Breakthrough in AI and Robotics 4PharmAthene Signs Agreement with Medison Pharma Ltd. to Commercialize and Distribute Biodefense Medical Countermeasures in Israel 2PharmAthene Signs Agreement with Medison Pharma Ltd. to Commercialize and Distribute Biodefense Medical Countermeasures in Israel 3PharmAthene Signs Agreement with Medison Pharma Ltd. to Commercialize and Distribute Biodefense Medical Countermeasures in Israel 4
(Date:7/25/2014)... 600 scientists from 25 countries and 35 states ... by the Genetics Society of America (GSA) next ... The conference will feature close to 500 presentations ... topics including gene expression and regulation, functional genomics, ... aging, and a variety of diseases. , ...
(Date:7/25/2014)... New research at the University of Adelaide has opened the ... resistance to powdery mildew. , In Australia, annual barley production ... year. Powdery mildew is one of the most important diseases ... team have discovered the composition of special growths on the ... the fungus into the leaf. , The research, by the ...
(Date:7/25/2014)... After development of diffusion tensor tractography (DTT), which ... reconstruction and estimation for three motor tracts, such ... the corticoreticular pathway became possible. The corticospinal tract ... for motor function in the human brain. Several ... tract by transtentorial herniation. In addition, some studies ...
Breaking Biology News(10 mins):Yeast meeting to showcase latest breakthroughs in genetics and molecular biology 2New hope for powdery mildew resistant barley 2
... Based on a pilot study in children with sarcoma, ... that immunotherapy could prove beneficial in treating high-risk forms ... novel dendritic vaccine as well as a standard flu ... Their findings, published in the August 1 issue ...
... surprisingly simple, inexpensive technique, chemists have found a way ... amounts of electricity, common chemicals and a room-temperature glass ... fuels, many researchers have proposed using solar electricity to ... when the sun goes down. One of the chief ...
... NY In the United States, Lyme disease is ... from animals to humans. These animal-borne diseases can make ... and effective intervention are crucial to protecting the public. ... Millbrook, NY recently received $750,000 in grant funding from ...
Cached Biology News:Immunotherapy in high-risk pediatric sarcomas shows promising response 2Immunotherapy in high-risk pediatric sarcomas shows promising response 3Water refineries? 2Water refineries? 3EPA funds ground-breaking Lyme disease research 2
MOUSE ANTI BOVINE CD335:ALEXA 488 Immunogen: Fusion protein consisting of the extracellular region of bovine CD335....
Template and primers for preparation of internal control spots...
AedestaTM Animal Organ/Tissue Perfusion Soln....
Cross reactivity to St. Louis encephalitis (MSI-7) is determined by ELISA....
Biology Products: